Skip to main content

Compugen Ltd. (CGEN)

NASDAQ: CGEN · IEX Real-Time Price · USD
4.59 0.17 (3.85%)
Dec 1, 2021 11:07 AM EST - Market open

Company Description

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe.

The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT.

Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.

It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid.

Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Compugen Ltd.
Compugen Logo
CountryUnited States
IPO DateAug 11, 2000
IndustryLife Sciences Tools & Services
SectorHealth Care
Employees68

Contact Details

Address:
Building D
Holon 5885849
Israel
Phone972 3 765 8585
Websitecgen.com

Stock Details

Ticker SymbolCGEN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001119774

Key Executives

NamePosition
Dr. Anat Cohen-DayagChief Executive Officer, President and Director
Ari KrashinChief Financial and Operating Officer
Dr. Oliver Froescheis Ph.D.Senior Vice President of Corporate and Business Development
Dr. Zurit LevineSenior Vice President of Technology Innovation
Dr. Henry Adewoye M.D.Senior Vice President and Chief Medical Officer
Yvonne NaughtonHead of Investor Relations and Corporate Communications
Donna GershowitzGeneral Counsel
Kirk A. Christoffersen MBASenior Vice President of Corporate and Business Development
Dorit AmitayVice President of Human Resources
Dr. Yaron Turpaz M.B.A., Ph.D., MBASenior Vice President and Senior Advisor of Computational Discovery

Latest SEC Filings

DateTypeTitle
Nov 22, 2021DNotice of Exempt Offering of Securities
Nov 19, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Nov 12, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 12, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Sep 2, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jul 29, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jul 28, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Jun 8, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
May 13, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Feb 25, 202120-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
View All SEC Filings